Alzheimer’s Disease (AD) is the most common form of dementia and displays a long preclinical phase. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in this phase has a protective effect and decreases the risk of developing AD cross-sectionally. However, the effects of NSAIDs therapy long-term on cerebral hemodynamics in this early phase is unclear. This is the first study to assess whether longitudinal use of NSAIDs (i.e., naproxen) has an impact on cerebral blood flow, and whether this is associated with a change in cognition and/or cerebrospinal fluid markers.
No takes yet. Share an insight, caveat, or question.
Sanami et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: